Dependence of Efavirenz-and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia

Journal of Infectious Diseases

Volumn 209, Issue 3, 2014, Pages 399-408

  Bertrand, Julie ^a,b   Verstuyft, Céline ^c,d   Chou, Monidarin ^e   Borand, Laurence ^f   Chea, Phalla ^f   Nay, Kuy Huong ^e   Blanc, François Xavier ^c   Mentré, France ^b   Taburet, Anne Marie ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d EA4123   (France)

^e University of Health Sciences   (France)

^f INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; BENZOXAZINES; CAMBODIA; CHROMATOGRAPHY, LIQUID; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; ISONIAZID; LAMIVUDINE; PLASMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RIFAMPIN; SPECTROPHOTOMETRY, ULTRAVIOLET; STAVUDINE; TUBERCULOSIS;

EID: 84892638671     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit466     Document Type: Article

References (50)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2013.
2. Rekic D, Roshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 2011; 71:536-43.
3. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 2006; 58:1017-23.
4. Borand L, Laureillard D, Madec Y, et al. Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg. Antivir Ther 2013; 18:419-23.
5. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
6. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
7. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8:743-59.
8. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
9. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-7.
10. Chou M, Bertrand J, Segeral O, et al. Population pharmacokineticpharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010; 54:4432-9.
11. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006; 62:267-75.
12. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-90.
13. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007; 5:349-53.
14. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19:1541-3.
15. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-302.
16. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2011; 68:689-95.
17. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011; 25:388-90.
18. Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90:406-13.
19. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004; 96:293-300.
20. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687-95.
21. Bertrand J, Chou M, Richardson DM, et al. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genomics 2012; 22:868-76.
22. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5?-promoter region polymorphism. Clin Pharmacol Ther 2000; 68:82-91.
23. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of longterm responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931-42.
24. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-9.
25. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 2003; 63:351-8.
26. Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther 2012; 91:1044-52.
27. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11:555-72.
28. Niemi M, Kivisto KT, Diczfalusy U, et al. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 2006; 16:565-8.
29. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36:164-72.
30. Sabbagh A, Darlu P. SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype. Genet Med 2006; 8:76-85.
31. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49:1733-8.
32. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-81.
33. Proust V, Toth K, Hulin A, Taburet AM, Gimenez F, Singlas E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J Chromatogr B Biomed Sci Appl 2000; 742:453-8.
34. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30:329-32.
35. Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 516G T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIVinfected South African children. Eur J Clin Pharmacol 2011; 68:339-47.
36. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogeneticsbased population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009; 85:485-94.
37. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 2009; 53:2346-53.
38. Siccardi M, Almond L, Schipani A, et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitroin vivo extrapolationmodel. Clin Pharmacol Ther 2012; 92:494-502.
39. Sanchez A, Cabrera S, Santos D, et al. Population pharmacokinetic/ pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother 2011; 55:5314-24.
40. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73:20-30.
41. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 2010; 6:95-103.
42. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012; 22:858-67.
43. Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS, Dandara C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 2012; 13:112.
44. Cho DY, Ogburn ET, Jones D, Desta Z. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother 2011; 55:1504-9.
45. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37:1793-6.
46. Gandhi M, Greenblatt RM, Bacchetti P, et al. A single-nucleotide polymorphism in CYP2B6 leads to 3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis 2012; 206:1453-61.
47. Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol 1983; 16:743-6.
48. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanismbased inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57:799-804.
49. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45:382-92.
50. Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. DrugMetab Dispos 2012; 40:717-25.